ENTRY       D06193                      Drug
NAME        Toralizumab (USAN/INN)
EFFICACY    Antineoplastic, Anti-CD154 antibody
  TYPE      Monoclonal antibody
COMMENT     Treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantation such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies (such as CLL/small lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma, relapsed/refractory Hodgkin's disease)
TARGET      TNFSF5 (CD154) [HSA:959] [KO:K03161]
  PATHWAY   hsa04060(959)  Cytokine-cytokine receptor interaction
            hsa04064(959)  NF-kappa B signaling pathway
            hsa04660(959)  T cell receptor signaling pathway
BRITE       Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Tumor necrosis factors
                TNFSF5 (CD154)
                 D06193  Toralizumab (USAN/INN)
DBLINKS     CAS: 252662-47-8
            PubChem: 47207851
///
